Vicore Pharma Holding AB (OSTO:VICO) Marketable Securities: kr682.37 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:VICO Vicore Pharma Holding AB OSTO:VICO
30 GF Score
Price kr11.36
! 2 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Marketable Securities?

Vicore Pharma Holding AB OSTO:VICO -0.87% 30 Marketable Securities is kr682.37 Mil as of Mar. 2026. GuruFocus rates OSTO:VICO with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Vicore Pharma Holding AB's Marketable Securities for the quarter that ended in Mar. 2026 was kr682.37 Mil.

Vicore Pharma Holding AB's annual Marketable Securities declined from Dec. 2023 (kr149.04 Mil) to Dec. 2024 (kr0.00 Mil) but then increased from Dec. 2024 (kr0.00 Mil) to Dec. 2025 (kr588.59 Mil).

Vicore Pharma Holding AB  (OSTO:VICO) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Vicore Pharma Holding AB Marketable Securities Related Terms

Vicore Pharma Holding AB Marketable Securities Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Marketable Securities Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.00 4.94 149.04 0.00 588.59

Vicore Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 333.29 585.38 365.78 588.59 682.37
OSTO:VICO
30GF Score
Vicore Pharma Holding AB OSTO:VICO
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of kr682.37 Mil mean?
Vicore Pharma Holding AB (OSTO:VICO) has a Marketable Securities of kr682.37 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Vicore Pharma Holding AB and its competitors.
Is Vicore Pharma Holding AB's Marketable Securities too high?
Vicore Pharma Holding AB's current Marketable Securities is kr682.37 Mil. Overall, Vicore Pharma Holding AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's Marketable Securities compare to VRTX and REGN?
Vicore Pharma Holding AB's Marketable Securities of kr682.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current Marketable Securities is kr682.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (OSTO:VICO) has a current Marketable Securities of kr682.37 Mil. The current Marketable Securities is kr682.37 Mil. Vicore Pharma Holding AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Vicore Pharma Holding AB (OSTO:VICO), the current Marketable Securities is kr682.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Other Exchanges 6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
30GF Score

Get the complete analysis for OSTO:VICO

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr11.36
Price